Immunotherapy for Infectious Diseases

172 Connick
2. Delta Coordinating Committee. Delta: a randomized double-blind controlled trial comparing
combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone
in HIV-infected individuals. Lancet 1996; 348:283–291.
3. Marschner IC, Collier AC, Coombs RW, et al. Use of changes in plasma levels of human
immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.
J Infect Dis 1998; 177:40–47.
4. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic
markers to clinical outcomes after nucleoside therapy in HIV infected adults with
200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology
Study Team. N Engl J Med 1996; 335:1091–1098.
5. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency
virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
N Engl J Med 1996; 334:1011–1017.
6. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues
plus indinavir in persons with human immunodeficiency virus infection and CD4
cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study
Team. N Engl J Med 1997; 337:725–733.
7. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and
lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral
therapy. N Engl J Med 1997; 337:734–739.
8. D’Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine
compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized,
double-blind, placebo-controlled trial. Ann Intern Med 1996; 124:1019–1030.
9. Riddler S, Stein D, Mayers D, et al. Durable clinical anti-HIV-1 activity (48 weeks) and
tolerability (24 weeks) for DMP 266 in combination with indinavir (IDV): DMP 266–003,
Cohort IV. In: Abstracts of the 35th Annual Meeting of the Infectious Diseases Society of
America, San Francisco, CA, 1997 [Abstract 770].
10. Albrecht M, Katzenstein D, Bosch RJ, et al. ACTG 364: virologic efficacy of nelfinavir
(NFV) and/or efavirenz (EFV) in combination with new nucleoside analogs in nucleoside
experienced subjects. In: Proceedings of the XII World AIDS Conference, Geneva,
Switzerland, 1998 [Abstract 12203].
11. Murphy RL, Gulick R, Smeaton L, et al. Treatment with indinavir, nevirapine, stavudine,
and 3TC following therapy with an amprenavir-containing regimen [Abstract OP2.4].
AIDS 1998; 12(suppl 4):S9.
12. Murphy RL, Gulick RM, DeGruttola V, et al. Treatment with amprenavir alone or amprenavir
with zidovudine and lamivudine in adults with human immunodeficiency virus
infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis 1999; 179:808–816.
13. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults. Updated recommendations
of the international AIDS society-USA panel. JAMA 2000; 283:381–390.
14. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, no. 10.
Atlanta, GA: CDC, 1999, p. 38.
15. Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDS-defining opportunistic
illnesses, 1992-1997. MMWR 1999; 48:1–22.
16. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among
patients with advanced human immunodeficiency virus infection. HIV Outpatient Study
Investigators. N Engl J Med 1998; 338:853–860.
17. Brodt HR, Kamps BS, Gute P, et al. Changing incidence of AIDS-defining illnesses in the
era of antiretroviral combination therapy. AIDS 1997; 11:1731–1738.
18. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies
in HIV infected people in Switzerland: prospective multicentre study. BMJ 1997;
315:1194–1199.